Mittie Doyle Biography and Net Worth

Insider of Avalo Therapeutics

Ms. Mittie Doyle is the Insider of Avalo Therapeutics.

What is Mittie Doyle's net worth?: The estimated net worth of Mittie Doyle is at least $48.53 thousand as of April 6th, 2026. Ms. Doyle owns 3,622 shares of Avalo Therapeutics stock worth more than $48,535 as of April 30th. This net worth estimate does not reflect any other assets that Ms. Doyle may own. Learn More about Mittie Doyle's net worth.
How do I contact Mittie Doyle?: The corporate mailing address for Ms. Doyle and other Avalo Therapeutics executives is 540 Gaither Rd Ste 400, Rockville, Maryland 20850-6713. Avalo Therapeutics can also be reached via phone at (410) 522-8707 and via email at [email protected]. Learn More on Mittie Doyle's contact information.
Has Mittie Doyle been buying or selling shares of Avalo Therapeutics?: During the last quarter, Mittie Doyle has sold $82,363.70 in shares of Avalo Therapeutics stock. Most recently, Mittie Doyle sold 3,970 shares of the business's stock in a transaction on Monday, April 6th. The shares were sold at an average price of $18.01, for a transaction totalling $71,499.70. Following the completion of the sale, the insider now directly owns 3,622 shares of the company's stock, valued at $65,232.22. Learn More on Mittie Doyle's trading history.
Who are Avalo Therapeutics' active insiders?: Avalo Therapeutics' insider roster includes Mittie Doyle (Insider), Schond Greenway (CFO), Christopher Sullivan (CAO), and H. Wilkins (Insider). Learn More on Avalo Therapeutics' active insiders.
Are insiders buying or selling shares of Avalo Therapeutics?: In the last year, insiders at the sold shares 5 times. They sold a total of 46,100 shares worth more than $764,724.33. The most recent insider tranaction occured on April, 6th when insider Mittie Doyle sold 3,970 shares worth more than $71,499.70. Insiders at Avalo Therapeutics own 4.5% of the company. Learn More about insider trades at Avalo Therapeutics.
Information on this page was last updated on 4/6/2026.

Mittie Doyle Insider Trading History at Avalo Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/6/2026	Sell	3,970	$18.01	$71,499.70	3,622
4/1/2026	Sell	679	$16.00	$10,864.00	3,622
3/16/2026	Sell	25,492	$16.15	$411,695.80	3,622

Mittie Doyle Buying and Selling Activity at Avalo Therapeutics

Avalo Therapeutics Company Overview

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Today's Range

Now: $13.40

$12.55

$13.58

50 Day Range

MA: $15.29

$12.86

$18.85

2 Week Range

Now: $13.40

$3.39

$20.72

Volume

713,644 shs

Average Volume

611,869 shs

Market Capitalization

$357.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93